Expanding the therapeutic applications of PARP inhibitors in cancer by targeting receptor tyrosine kinases

Puntos clave

• Incorporating receptor tyrosine kinases with PARP inhibitors might enhance cancer treatment efficacy, revealing new combinations to combat disease.
• Research indicates potential benefits of PARP inhibitors in various cancer types, particularly when targeting specific molecular pathways like receptor tyrosine kinases.
• Employing PARP inhibitors in tandem with receptor tyrosine kinase targeting is a promising strategy for personalized cancer therapy.
• Further validation is needed for these combined approaches, as the interaction with the tumor microenvironment remains to be fully understood.